Effect of pravastatin and atorvastatin on glucose metabolism in non-diabetic patients with hypercholesterolemia

Internal Medicine

Volumn 45, Issue 2, 2006, Pages 51-55

  Ishikawa, Michiro ^a   Namiki, Atsushi ^b   Kubota, Tetsuya ^a   Yajima, Suguru ^a   Fukazawa, Masayuki ^a   Moroi, Masao ^a   Sugi, Kaoru ^a  

^a TOHO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atorvastatin; Glucose metabolism; Lipid metabolism; Pravastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; STATISTICAL ANALYSIS;

AGED; ANTICHOLESTEREMIC AGENTS; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; FEMALE; GLUCOSE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; PRAVASTATIN; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33344471035     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.1476     Document Type: Article

References (17)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995.
2. Menys VC, Durrington PN. Squalene synthase inhibitors. Br J Pharmacol 139: 881-882, 2003.
3. Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 58: 614-618, 2004.
4. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 58: 303-309, 2004.
5. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183-1197, 1997.
6. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a prospective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357-362, 2001.
7. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361: 1149-1158, 2003.
8. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696, 2004.
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361: 2005-2016, 2003.
10. MS Sabatine, SD Wiviott, DA Morrow, CH McCabe, CP Cannon. TIMI Study Group. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 110 (Suppl III): 111-834, 2004 (Abstract).
11. Rosenson RS, Trangney CC, Casey LC. Inhibition of proinflammatory cytokines production by pravastatin. Lancet 353: 983-984, 1999.
12. Yudkin JS, Stehouwer CD, Emesis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972-978, 1999.
13. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89: 2519-2524, 1994.
14. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19: 117-125, 2005.
15. Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J 295: 31-40, 1993.
16. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 13: 76-79, 2005.
17. 2+ channels in rat islet β-cells. Br J Pharmacol 126: 1205-1213, 1999.